Search Results for "Quantos Anos Dura O Curso De Farmacia"

03:32 EDT 25th May 2015 | BioPortfolio

Matching Channels

None

Matching News

Electronic dura mater implants

Electronic dura mater soft implants could be useful for delivering therapeutic electronic impulses and compounds to treat spinal cord injury (SCI) and other CNS conditions.

Admedus Limited expands market for ADAPT® tissue products

Admedus Limited (ASX:AHZ) is expanding its regenerative tissue portfolio into additional large target repair markets following successful initial results from a pre-clinical study of ADAPT® treate...

DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery

WEST CHESTER, Pa., May 4, 2015 /PRNewswire/ -- DePuy Synthes CMF* today announced the launch of SYNTHECEL® Dura Repair, the first commercially available biosynthesized dural replacement derived f...

Neuroprosthetics for paralysis: Biocompatible, flexible implant slips into the spinal cord

New therapies are on the horizon for individuals paralyzed following spinal cord injury. The e-Dura implant developed by EPFL scientists can be applied directly to the spinal cord without causing dama...

DePuy Synthes launches cellulose-based dural replacement for neurosurgery

DePuy Synthes CMF announced the launch of SYNTHECEL Dura Repair, the first commercially available biosynthesized dural replacement derived from cellulose for use in neurosurgery.

Spinal Cord Implant Mimics Living Tissue

New therapies are on the horizon for individuals paralyzed following spinal cord injury -- the e-Dura implant developed by EPFL scientists can be applied directly to the spinal cord without causing da...

Neuroprosthetics for Paralysis: New Implant on the Spinal Cord

EPFL scientists have managed to get rats walking on their own again using a combination of electrical and chemical stimulation. But applying this method to humans would require multifunctional implant...

Admedus receives A$0.20 price target from Morgans

Admedus Limited (ASX:AHZ) remains one of Morgans’ High Conviction calls in 2015, which also has an Add recommendation with a price target of A$0.20.The broker noted that with the A$28 million ca...

Matching PubMed Articles

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement